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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
test scores after 28 days. Together, these 
studies show that lixivaptan can increase 
serum sodium in patients with euvolemic 
hyponatremia, but further research is 
needed to identify the patients most 
likely to experience meaningful benefit 
from clinical treatment with vaptans. 
See page 1215 and page 1223.
Mouse model 
of transplant 
nephropathy
Chronic allograft vasculopathy, char-
acterized by transplant arteriosclerosis 
involving intrarenal vessels, is an impor-
tant contributor to renal allograft loss. 
Until now, no murine model existed 
that replicated the findings of transplant 
vasculopathy. Zarjou and colleagues 
report a novel mouse orthotopic kidney 
transplant model that develops severe 
tubulointerstitial fibrosis and severe 
Lixivaptan for 
inpatient and 
outpatient 
hyponatremia
Hyponatremia is the most common 
electrolyte disorder in hospitalized and 
ambulatory patients. Lixivaptan is an 
oral vasopressin V2-receptor antagonist 
that has been shown to increase plasma 
sodium in hyponatremic patients in 
phase 2 studies. As reported in this issue, 
two phase 3 multicenter randomized 
controlled trials examine the efficacy of 
lixivaptan in patients with hyponatremia. 
In the LIBRA study, 106 hospitalized 
patients with euvolemic hyponatremia 
(sodium <130 mmol/l) were randomized 
to receive lixivaptan or placebo in addi-
tion to fluid restriction. Patients who 
received lixivaptan had a greater rise in 
serum sodium after 7 days (6.7 versus 4.5 
mmol/l), but the difference was not sig-
nificant after 30 days of treatment. There 
was no important difference in adverse 
events between the treatment groups. In 
the HARMONY study, 206 outpatients 
with euvolemic hyponatremia (sodium 
<135 mmol/l) were randomized to lix-
ivaptan or placebo. Patients receiving 
lixivaptan had a greater rise in serum 
sodium than those assigned to placebo 
after 7 days, but there was no differ-
ence in sodium or neuropsychological 
intrarenal vasculopathy characterized 
by perivascular leukocytic infiltration 
and neointimal hyperplasia. This model 
promises to provide investigators with 
an important new tool that may help 
develop strategies to prevent and treat 
allograft vasculopathy. See page 1231.
Ischemic 
preconditioning  
and microRNA
Delayed ischemic preconditioning 
(IPC) describes the protection conferred 
by transient tissue ischemia against a 
subsequent ischemic insult occurring 
days to weeks later. Xu et al. studied the 
role of the microRNA miR-21 in medi-
ating IPC-induced protection against 
acute kidney injury (AKI). They report 
that suppression of miR-21 expression 
prevents IPC from protecting mice from 
renal ischemia–reperfusion injury (IRI) 
and that miR-21 suppresses expres-
sion of proapoptotic factors in mice 
subjected to IRI. This study provides 
novel insights into the mechanism by 
which IPC and microRNA protect the 
kidney from ischemic injury. Future 
studies will need to determine whether 
administering exogenous miR-21 or 
upregulating endogenous miR-21 can 
prevent or reduce the severity of AKI. 
See page 1167.
